Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

232
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
232
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

360
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
360
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

288
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
288
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

286
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
286
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

320
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
320
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

536
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
536

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Screening of Avoidance/Restrictive Food Intake Disorder (ARFID) in Patients with Quiescent Inflammatory Bowel Disease and Irritable Bowel Syndrome-Like Symptoms.

Digestive diseases and sciences·2026
Same author

Occurrence of multidrug-resistant extended-spectrum β-lactamase (ESBL)-producing <i>Escherichia coli</i> in fecal and environmental samples from Belgian livestock farms.

Microbiology spectrum·2026
Same author

First proctological application of a noncontact nitrous oxide cryotherapy device treating nonmalignant intra- and perianal HPV-related lesions.

Techniques in coloproctology·2026
Same author

Development of S.Tool: An electronic diary for assessing bowel symptoms after rectal cancer surgery.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Preferences and acceptability of telemedicine in Belgian IBD patients.

Acta gastro-enterologica Belgica·2026
Same authorSame journal

Recurrent gastrointestinal bleeding after Peptide Receptor Radionuclide Therapy for a small intestine neuroendocrine tumor.

Acta gastro-enterologica Belgica·2026
Same journal

A rare twist in the abdomen: diagnostic and therapeutic approaches to omental infarction - a case report and literature review.

Acta gastro-enterologica Belgica·2026
Same journal

GLP-1 receptor agonist-associated eosinophilic duodenitis presenting as a bowel obstruction : a case report and literature review.

Acta gastro-enterologica Belgica·2026
Same journal

Ampullary Actinomycosis Mimicking Malignancy: A Case Report and Literature Review.

Acta gastro-enterologica Belgica·2026
Same journal

A little known cause of ischemic colitis.

Acta gastro-enterologica Belgica·2026
Same journal

Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle.

Acta gastro-enterologica Belgica·2026
See all related articles

Related Experiment Video

Updated: Sep 7, 2025

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

551

Belgian consensus on irritable bowel syndrome.

S Kindt1, H Louis2, H De Schepper3

  • 1Department of gastroenterology and Hepatology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussel, Belgium.

Acta Gastro-Enterologica Belgica
|June 16, 2022
PubMed
Summary
This summary is machine-generated.

Belgian experts reached consensus on Irritable Bowel Syndrome (IBS) management, emphasizing multifactorial causes and positive diagnosis. First-line treatments include lifestyle changes and specific diets, with restricted use of others.

Keywords:
Delphi consensusdiagnosisirritable bowel syndromereviewtreatment

More Related Videos

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.4K
In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments
10:32

In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments

Published on: October 25, 2016

11.6K

Related Experiment Videos

Last Updated: Sep 7, 2025

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

551
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.4K
In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments
10:32

In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments

Published on: October 25, 2016

11.6K

Area of Science:

  • Gastroenterology
  • Clinical Practice Guidelines
  • Digestive Health

Background:

  • Irritable Bowel Syndrome (IBS) is a prevalent condition characterized by abdominal pain and altered bowel habits.
  • Despite its prevalence, significant uncertainties remain in the diagnosis and treatment of IBS.
  • Current clinical practice faces challenges in managing IBS effectively.

Purpose of the Study:

  • To establish a consensus among Belgian experts on the diagnosis and management of IBS.
  • To provide evidence-based recommendations tailored to the Belgian healthcare system.
  • To address uncertainties in current IBS clinical practice.

Main Methods:

  • A Delphi consensus process involving 20 Belgian experts.
  • Literature review and a voting procedure on 78 statements.
  • Application of Grading of Recommendations, Assessment, Development and Evaluation (GRADE) criteria.

Main Results:

  • Consensus was reached on 50 statements regarding IBS.
  • Agreed on multifactorial etiology, with abdominal discomfort as a key symptom.
  • Recommended positive diagnosis through history and examination, limiting additional tests unless alarm features are present.
  • Identified lifestyle modification, spasmolytics, and soluble fibers as first-line treatments.
  • Supported low FODMAP diet, probiotics, and CBT as appropriate therapies.
  • Discouraged fecal microbiota transplantation and gluten-free diets.

Conclusions:

  • The consensus provides a summary of current evidence on IBS etiology, symptoms, diagnosis, and treatment.
  • Highlights the importance of a positive diagnostic approach and patient education.
  • Offers specific guidance for IBS management within the Belgian healthcare context.